XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value Measurements (Tables)
 6 Months Ended
Jun. 26, 2020
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

June 26,
2020
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$30.9  $21.0  $9.9  $—  
Equity securities
28.2  28.2  —  —  
$59.1  $49.2  $9.9  $—  

Liabilities:
Deferred compensation liabilities
$29.6  $—  $29.6  $—  
Contingent consideration and acquired contingent liabilities
39.1  —  —  39.1  
Settlement Warrants35.1  —  —  35.1  

$103.8  $—  $29.6  $74.2  
December 27,
2019
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$30.6  $21.0  $9.6  $—  
Equity securities
26.2  26.2  —  —  
$56.8  $47.2  $9.6  $—  
Liabilities:
Deferred compensation liabilities
$39.2  $—  $39.2  $—  
Contingent consideration and acquired contingent liabilities
69.3  —  —  69.3  
Settlement Warrants43.4  —  —  43.4  
$151.9  $—  $39.2  $112.7  
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 27, 2019$69.3  
Payments
(25.0) 
Accretion expense
0.5  
Fair value adjustments
(5.7) 
Balance as of June 26, 2020$39.1  
Schedule of Share-based Payment Awared, Warrants, Valuation Assumptions [Table Text Block] [Table Text Block]
The key assumptions used to estimate the fair value of the Settlement Warrants were as follows:
June 26,
2020		December 27, 2019
Expected share price volatility63.1 %54.4 %
Weighted-average risk-free rate0.5 %1.8 %
Expected annual dividend per share— %— %
Weighted-average expected term (in years)7.67.6
Share price$2.77  $3.45  
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
June 26, 2020December 27, 2019
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
4.875% senior notes due April 2020$—  $—  $614.8  $480.0  
5.75% senior notes due August 2022610.3  149.6  610.3  251.0  
4.75% senior notes due April 2023133.7  20.2  133.7  53.7  
5.625% senior notes due October 2023514.7  100.4  514.7  193.2  
5.50% senior notes due April 2025387.2  59.5  387.2  135.5  
10.00% first lien senior notes due April 2025495.0  420.2  —  —  
10.00% second lien senior notes due April 2025322.9  194.5  322.9  253.8  
Revolving credit facility900.0  900.0  900.0  900.0  
Level 2:
9.50% debentures due May 202210.4  3.6  10.4  5.4  
8.00% debentures due March 20234.4  1.1  4.4  2.0  
Term loan due September 20241,513.0  1,121.3  1,520.8  1,240.0  
Term loan due February 2025401.5  296.7  403.6  326.2  
Total Debt$5,293.1  $3,267.1  $5,422.8  $3,840.8  
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
Three Months EndedSix Months Ended
June 26,
2020		June 28,
2019		June 26,
2020		June 28,
2019
CuraScript, Inc.
30.2 %31.9 %27.5 %29.8 %
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
June 26,
2020		December 27,
2019
AmerisourceBergen Corporation
27.1 %31.3 %
McKesson Corporation
17.1  15.3  
CuraScript, Inc.
11.5  12.1  

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge related to the Medicaid lawsuit:
Three Months EndedSix Months Ended
June 26,
2020		June 28,
2019		June 26,
2020		June 28,
2019
Acthar Gel30.5 %32.4 %27.9 %30.4 %
INOmax22.1  17.0  21.7  18.0  
Ofirmev*11.0  *11.5  
*Net sales from this product were less than 10% of total net sales during the respective periods presented above.